default author photo

Ly Dsouza

University of Texas at Houston - Department of Lymphoma and Myeloma

Houston, TX

United States

SCHOLARLY PAPERS

1

DOWNLOADS

0

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Safety and Activity of Pembrolizumab in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Posted: 01 Mar 2021
University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma

Abstract:

Loading...